Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 24 (11), 1662-1668

BRAF Somatic Mutation Contributes to Intrinsic Epileptogenicity in Pediatric Brain Tumors

Affiliations

BRAF Somatic Mutation Contributes to Intrinsic Epileptogenicity in Pediatric Brain Tumors

Hyun Yong Koh et al. Nat Med.

Abstract

Pediatric brain tumors are highly associated with epileptic seizures1. However, their epileptogenic mechanisms remain unclear. Here, we show that the oncogenic BRAF somatic mutation p.Val600Glu (V600E) in developing neurons underlies intrinsic epileptogenicity in ganglioglioma, one of the leading causes of intractable epilepsy2. To do so, we developed a mouse model harboring the BRAFV600E somatic mutation during early brain development to reflect the most frequent mutation, as well as the origin and timing thereof. Therein, the BRAFV600E mutation arising in progenitor cells during brain development led to the acquisition of intrinsic epileptogenic properties in neuronal lineage cells, whereas tumorigenic properties were attributed to high proliferation of glial lineage cells. RNA sequencing analysis of patient brain tissues with the mutation revealed that BRAFV600E-induced epileptogenesis is mediated by RE1-silencing transcription factor (REST), which is a regulator of ion channels and neurotransmitter receptors associated with epilepsy. Moreover, we found that seizures in mice were significantly alleviated by an FDA-approved BRAFV600E inhibitor, vemurafenib, as well as various genetic inhibitions of Rest. Accordingly, this study provides direct evidence of a BRAF somatic mutation contributing to the intrinsic epileptogenicity in pediatric brain tumors and suggests that BRAF and REST could be treatment targets for intractable epilepsy.

Comment in

  • Linking Brain Tumors and Epileptic Seizures
    JM Mulcahy Levy et al. Nat Med 24 (11), 1638-1639. PMID 30374199.
    Mutationally activated BRAFV600E influences the behavior of different types of cells in the brain and leads to promotion of seizures as well as brain tumors, i …

Similar articles

See all similar articles

Cited by 7 PubMed Central articles

  • Neurodevelopmental Aspects of RASopathies
    YE Kim et al. Mol Cells 42 (6), 441-447. PMID 31250618. - Review
    RAS gene mutations are frequently found in one third of human cancers. Affecting approximately 1 in 1,000 newborns, germline and somatic gain-of-function mutations …
  • Oncogenic BRAF Alterations and Their Role in Brain Tumors
    F Behling et al. Cancers (Basel) 11 (6). PMID 31181803. - Review
    Alterations of the v-raf murine sarcoma viral oncogene homolog B (BRAF) have been extensively studied in several tumor entities and are known to drive cell growth in seve …
  • Clinical Pearls and Advances in Molecular Researches of Epilepsy-Associated Tumors
    JH Phi et al. J Korean Neurosurg Soc 62 (3), 313-320. PMID 31085957.
    Brain tumors are the second most common type of structural brain lesion that causes chronic epilepsy. Patients with low-grade brain tumors often experience chronic drug-r …
  • The Role of Somatic Mutational Events in the Pathogenesis of Epilepsy
    PH Iffland 2nd et al. Curr Opin Neurol 32 (2), 191-197. PMID 30762606. - Review
    Defining somatic gene mutations in brain tissue specimens has shed new light on how MCD form and the mechanisms of epileptogenesis associated with MCD. Trials of mTOR inh …
  • Linking Brain Tumors and Epileptic Seizures
    JM Mulcahy Levy et al. Nat Med 24 (11), 1638-1639. PMID 30374199.
    Mutationally activated BRAFV600E influences the behavior of different types of cells in the brain and leads to promotion of seizures as well as brain tumors, i …
See all "Cited by" articles

Publication types

MeSH terms

Substances

LinkOut - more resources

Feedback